ERBB2 and breast carcinoma: Specifically, we focus on two subgroups of patients with advanced (unresectable locally advanced or metastatic) breast cancer: triple-negative breast cancer (TNBC) and hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer.